ACT-541468
DrugACT-541468 will be administered as 50 mg tablets for oral use.
NCT Number: NCT03657355
This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Altasciences Company Inc., Montreal, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ACT-541468 will be administered as 50 mg tablets for oral use.
Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
Matching-placebo will be used.
Time frame: Duration: for up to 24 hours post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 24 hours post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 12 hours post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 12 hours post-dose
Time frame: Duration: for up to 24 hours post-dose
Time frame: Duration: for up to 1 hour post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 24 hours post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 24 hours post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 24 hours post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 24 hours post-dose
VAS = visual analogue scale
Time frame: Duration: for up to 24 hours post-dose
Time frame: Duration: for up to 24 hours post-dose
Time frame: Duration: for up to 8 hours post-dose
Time frame: Duration: for up to 8 hours post-dose
Time frame: Duration: for up to 8 hours post-dose
Time frame: Duration: for up to 24 hours post-dose
Time frame: Duration: for up to 24 hours post-dose
Time frame: Duration: for up to 24 hours post-dose
Time frame: Duration: for up to 24 hours post-dose
Time frame: Duration: for up to 24 hours post-dose
Time frame: All AEs from (first) admittance on Day -1 up to EOS, i.e. for up to 9 weeks
Time frame: SAE reporting: from signature of informed consent up to EOS, i.e. for up to 13 weeks
Idorsia Pharmaceuticals Ltd.
Industry
Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.